Transurethral Cylindrical Water Sac Prostate Enlargement Surgery for the Treatment of Small-Volume Benign Prostatic Hyperplasia: A Retrospective Analysis.
{"title":"Transurethral Cylindrical Water Sac Prostate Enlargement Surgery for the Treatment of Small-Volume Benign Prostatic Hyperplasia: A Retrospective Analysis.","authors":"Tingbo Fu, Xinjie Jiang, Guojun Li, Lizhuan Liu, Youjiao Chen, Junfeng Mo","doi":"10.62713/aic.3574","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To investigate the clinical efficacy of transurethral columnar balloon dilation of prostate (TUCBDP) in the treatment of small-volume benign prostatic hyperplasia (BPH) and provide the optimal treatment for the surgical treatment of small volume benign prostatic hyperplasia.</p><p><strong>Methods: </strong>This retrospective study analyzed 106 patients with small-volume BPH who underwent surgical treatment at the Department of Urology, Xiangya Changde Hospital from December 2023 to January 2024. The patients were divided into two groups based on the type of surgery received: TUCBDP group (n = 53) and transurethral resection of prostate (TURP) group (n = 53), which serves as the control group. We observed and measured the primary outcome indexes of the two groups, including international prostate symptom score (IPSS), maximum urinary flow rate (Qmax), postvoid residual (PVR), and quality of life (QoL) score, as well as the secondary outcome indicators, such as operation time, hospital stay, indwelling catheter time, the frequency of night urination and daytime urination, and the total incidence of long-term and short-term complications.</p><p><strong>Results: </strong>Preoperative IPSS, Qmax, PVR, and QoL scores showed no significant differences between the TUCBDP and TURP groups (p > 0.05). Postoperatively, the TUCBDP group showed superior results in terms of shortened operation time (-15.96 minutes, 95% confidence interval (CI) [-20.06, -11.86], p < 0.001), hospitalization time (-1.73 days, 95% confidence interval (CI) [-2.26, -1.20], p < 0.001), and indwelling catheter time (-1.17 days, 95% CI [-1.55, -0.79], p < 0.001), reduced night urination frequency (-0.71 times, 95% CI [-0.89, -0.53], p < 0.001) and daytime urination frequency (-1.80 times, 95% CI [-2.25, -1.35], p < 0.001). For patients receiving TUCBDP, improvements were also noted in IPSS (-2.27, 95% CI [-3.58, -0.96], p < 0.001), Qmax (4.50 mL/s, 95% CI [3.30, 5.70], p < 0.001), PVR (-6.89 mL, 95% CI [-9.48, -4.30], p < 0.001), and QoL (-0.87, 95% CI [-1.57, -0.17], p = 0.026). The TUCBDP group also had lower rates of near-term (15.09% vs. 35.85%, χ2 = 6.013, p = 0.014) and long-term complications (11.32% vs. 37.74%, χ2 = 9.988, p = 0.002).</p><p><strong>Conclusions: </strong>TUCBDP demonstrates significant clinical efficacy in the treatment of small-volume BPH, causing a low incidence of postoperative complications.</p>","PeriodicalId":8210,"journal":{"name":"Annali italiani di chirurgia","volume":"95 6","pages":"1155-1162"},"PeriodicalIF":0.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annali italiani di chirurgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62713/aic.3574","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To investigate the clinical efficacy of transurethral columnar balloon dilation of prostate (TUCBDP) in the treatment of small-volume benign prostatic hyperplasia (BPH) and provide the optimal treatment for the surgical treatment of small volume benign prostatic hyperplasia.
Methods: This retrospective study analyzed 106 patients with small-volume BPH who underwent surgical treatment at the Department of Urology, Xiangya Changde Hospital from December 2023 to January 2024. The patients were divided into two groups based on the type of surgery received: TUCBDP group (n = 53) and transurethral resection of prostate (TURP) group (n = 53), which serves as the control group. We observed and measured the primary outcome indexes of the two groups, including international prostate symptom score (IPSS), maximum urinary flow rate (Qmax), postvoid residual (PVR), and quality of life (QoL) score, as well as the secondary outcome indicators, such as operation time, hospital stay, indwelling catheter time, the frequency of night urination and daytime urination, and the total incidence of long-term and short-term complications.
Results: Preoperative IPSS, Qmax, PVR, and QoL scores showed no significant differences between the TUCBDP and TURP groups (p > 0.05). Postoperatively, the TUCBDP group showed superior results in terms of shortened operation time (-15.96 minutes, 95% confidence interval (CI) [-20.06, -11.86], p < 0.001), hospitalization time (-1.73 days, 95% confidence interval (CI) [-2.26, -1.20], p < 0.001), and indwelling catheter time (-1.17 days, 95% CI [-1.55, -0.79], p < 0.001), reduced night urination frequency (-0.71 times, 95% CI [-0.89, -0.53], p < 0.001) and daytime urination frequency (-1.80 times, 95% CI [-2.25, -1.35], p < 0.001). For patients receiving TUCBDP, improvements were also noted in IPSS (-2.27, 95% CI [-3.58, -0.96], p < 0.001), Qmax (4.50 mL/s, 95% CI [3.30, 5.70], p < 0.001), PVR (-6.89 mL, 95% CI [-9.48, -4.30], p < 0.001), and QoL (-0.87, 95% CI [-1.57, -0.17], p = 0.026). The TUCBDP group also had lower rates of near-term (15.09% vs. 35.85%, χ2 = 6.013, p = 0.014) and long-term complications (11.32% vs. 37.74%, χ2 = 9.988, p = 0.002).
Conclusions: TUCBDP demonstrates significant clinical efficacy in the treatment of small-volume BPH, causing a low incidence of postoperative complications.
目的：探讨经尿道前列腺柱状球囊扩张术（TUCBDP）治疗小体积良性前列腺增生（BPH）的临床疗效，为小体积良性前列腺增生的手术治疗提供最佳方案。方法：回顾性分析湘雅常德医院泌尿外科2023年12月至2024年1月手术治疗的106例小体积前列腺增生患者。根据手术类型将患者分为两组：TUCBDP组（n = 53）和经尿道前列腺切除术（TURP）组（n = 53），经尿道前列腺切除术（TURP）组为对照组。观察并测量两组患者的主要结局指标：国际前列腺症状评分（IPSS）、最大尿流率（Qmax）、尿后残留（PVR）、生活质量（QoL）评分；次要结局指标：手术时间、住院时间、留置导尿管时间、夜间和白天排尿次数、长短期并发症总发生率。结果：术前IPSS、Qmax、PVR、QoL评分在TUCBDP组与TURP组间差异无统计学意义（p < 0.05）。术后，TUCBDP组在缩短手术时间（-15.96分钟，95%可信区间（CI） [-20.06, -11.86], p < 0.001）、住院时间（-1.73天，95%可信区间（CI） [-2.26, -1.20], p < 0.001）、留置导尿管时间（-1.17天，95% CI [-1.55, -0.79], p < 0.001）、减少夜间排尿次数（-0.71次，95% CI [-0.89, -0.53], p < 0.001）、减少日间排尿次数（-1.80次，95% CI[-2.25, -1.35]）、减少夜间排尿次数（-0.71次，95% CI [- 2.06, -11.86], p < 0.001）、P < 0.001)。对于接受TUCBDP治疗的患者，IPSS （-2.27, 95% CI [-3.58, -0.96], p < 0.001）、Qmax （4.50 mL/s, 95% CI [3.30, 5.70], p < 0.001）、PVR （-6.89 mL, 95% CI [-9.48, -4.30], p < 0.001）和QoL （-0.87, 95% CI [-1.57, -0.17], p = 0.026）也有改善。TUCBDP组近期并发症发生率（15.09%比35.85%,χ2 = 6.013, p = 0.014）和远期并发症发生率（11.32%比37.74%,χ2 = 9.988, p = 0.002）均较低。结论：TUCBDP治疗小体积BPH临床疗效显著，术后并发症发生率低。
期刊介绍：
Annali Italiani di Chirurgia is a bimonthly journal and covers all aspects of surgery:elective, emergency and experimental surgery, as well as problems involving technology, teaching, organization and forensic medicine. The articles are published in Italian or English, though English is preferred because it facilitates the international diffusion of the journal (v.Guidelines for Authors and Norme per gli Autori). The articles published are divided into three main sections:editorials, original articles, and case reports and innovations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
